Charles River Laboratories International, Inc. $CRL Stock Position Raised by Signaturefd LLC

Key Points

• Signaturefd LLC increased its Charles River Laboratories position by 563.5% in the third quarter, bringing its holdings to 8,865 shares valued at approximately $2.6 million. Institutional investors collectively own 98.91% of the company.
• Charles River reported quarterly EPS of $3.02, exceeding analysts’ $2.77 estimate, while revenue reached $1 billion but declined 2.7% year over year. The company issued fiscal 2026 EPS guidance of $11.15–$11.45.
• Analysts maintain a consensus “Moderate Buy” rating, with an average price target of $302.33; meanwhile, insiders sold 94,127 shares worth about $26.8 million over the past 90 days.

Signaturefd LLC boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 563.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,865 shares of the medical research company's stock after buying an additional 7,529 shares during the period. Signaturefd LLC's holdings in Charles River Laboratories International were worth $2,615,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Amundi lifted its position in shares of Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company's stock valued at $133,397,000 after acquiring an additional 492,301 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Charles River Laboratories International by 14.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock worth $285,001,000 after purchasing an additional 210,260 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in Charles River Laboratories International by 230.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company's stock valued at $59,044,000 after purchasing an additional 142,716 shares during the last quarter. State of Alaska Department of Revenue raised its stake in Charles River Laboratories International by 2,268.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 111,781 shares of the medical research company's stock valued at $32,977,000 after purchasing an additional 107,061 shares during the last quarter. Finally, Ranger Investment Management L.P. acquired a new position in Charles River Laboratories International in the 1st quarter valued at $12,198,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Trading Down 0.1%

Shares of Charles River Laboratories International stock opened at $345.08 on Monday. The stock has a 50 day moving average of $294.35 and a 200 day moving average of $233.67. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The firm has a market capitalization of $16.47 billion, a price-to-earnings ratio of -71.15, a PEG ratio of 3.23 and a beta of 1.40. Charles River Laboratories International, Inc. has a fifty-two week low of $146.20 and a fifty-two week high of $351.21.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm's quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the company posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, research analysts predict that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current year.

Insider Activity

In other Charles River Laboratories International news, Director Nancy C. Andrews sold 573 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the sale, the director owned 1,438 shares of the company's stock, valued at approximately $410,175.12. This trade represents a 28.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Victoria L. Creamer sold 4,179 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president directly owned 30,051 shares in the company, valued at $7,788,017.16. This trade represents a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 94,127 shares of company stock valued at $26,776,516 over the last 90 days. Insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on CRL. Morgan Stanley raised their price objective on Charles River Laboratories International from $300.00 to $340.00 and gave the company an "overweight" rating in a report on Monday, October 12th. Evercore set a $330.00 target price on shares of Charles River Laboratories International in a report on Friday, September 25th. Robert W. Baird increased their target price on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the company an "outperform" rating in a research report on Friday, September 25th. Royal Bank Of Canada raised their price target on shares of Charles River Laboratories International from $282.00 to $322.00 and gave the stock an "outperform" rating in a research note on Friday, September 25th. Finally, TD Cowen raised their price target on shares of Charles River Laboratories International from $300.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday, September 25th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $302.33.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.